| Literature DB >> 21075334 |
Craig J Galbán1, Stefanie Galbán, Marcian E Van Dort, Gary D Luker, Mahaveer S Bhojani, Alnawaz Rehemtulla, Brian D Ross.
Abstract
Today molecular imaging technologies play a central role in clinical oncology. The use of imaging techniques in early cancer detection, treatment response, and new therapy development is steadily growing and has already significantly impacted on clinical management of cancer. In this chapter, we overview three different molecular imaging technologies used for the understanding of disease biomarkers, drug development, or monitoring therapeutic outcome. They are (1) optical imaging (bioluminescence and fluorescence imaging), (2) magnetic resonance imaging (MRI), and (3) nuclear imaging (e.g., single-photon emission computed tomography (SPECT) and positron emission tomography (PET)). We review the use of molecular reporters of biological processes (e.g., apoptosis and protein kinase activity) for high-throughput drug screening and new cancer therapies, diffusion MRI as a biomarker for early treatment response and PET and SPECT radioligands in oncology.Entities:
Mesh:
Year: 2010 PMID: 21075334 PMCID: PMC4327770 DOI: 10.1016/B978-0-12-385071-3.00009-5
Source DB: PubMed Journal: Prog Mol Biol Transl Sci ISSN: 1877-1173 Impact factor: 3.622